Myostatin
Myostatin (growth/differentiation factor 8)
Written by Aaron CuhaReviewed Sep 2026
Also known as: GDF8, GDF-8, MSTN
The brake on muscle growth. Knock it out in a mouse and you get a mouse twice as muscular, which launched a field. In primates the dominant brake turns out to be a different protein.
Overview
Myostatin is made by skeletal muscle and acts back on skeletal muscle to restrain its growth. It is a chalone, a signal whose job is to stop a tissue getting bigger. Delete it in a mouse and you get an animal two to three times more muscular, a 1997 result that created an entire drug industry and a great deal of supplement marketing.
The human story is more complicated and more interesting. Antibodies that block myostatin alone have mostly failed in trials. The best explanation came from a monkey study showing that in primates it is activin A, not myostatin, that dominates the restraint on muscle mass. That reframing is why drugs that block the receptor both signals share have done more than drugs that block myostatin specifically, and it is why anything sold to you as a myostatin inhibitor deserves hard questions.
Mechanism of action
Circulates as a latent disulfide-linked dimer held inactive by its own propeptide. Once activated it signals through activin type II receptors, principally ActRIIB, with type I receptors ALK4 and ALK5, through SMAD2 and SMAD3, to suppress muscle protein synthesis and satellite cell activity. Activin A signals through the same type II receptors, which is the whole reason receptor-level blockade and ligand-level blockade behave so differently.
Human evidence
Substantial, and mostly a record of failure for the obvious approach. Blocking myostatin alone has repeatedly not worked in people. Blocking the receptor it shares with activin A, or blocking myostatin activation rather than the mature protein, has worked.
- Domagrozumab, a pure anti-myostatin antibody in Duchenne muscular dystrophy: p = 0.94 on the co-primary functional endpoint, nothing significant in any secondary, muscle volume gains not significant.
- Landogrozumab, another anti-myostatin antibody, was studied in a phase 2 after hip arthroplasty.
- Apitegromab, which blocks the activation of pro and latent myostatin, has positive phase 3 data in nonambulatory spinal muscular atrophy in 188 participants already on standard therapy.
- Bimagrumab, which blocks the activin type II receptor and so neutralises myostatin and activin A together, produced large randomised changes in body composition: fat mass down 20.5%, lean mass up 3.6% at 48 weeks.
- A single human case report describes a child with a myostatin loss-of-function mutation and gross muscle hypertrophy.
What this does not tell you: One case report is not a safety profile. The primate finding that activin A matters more than myostatin means results from myostatin-specific agents may not generalise the way the mouse work implied. And the most striking body composition result in this pathway, bimagrumab, came from receptor blockade that is not myostatin-specific at all, so crediting it to myostatin inhibition is a category error. Separately, bimagrumab added lean mass in older adults with sarcopenia without improving any measure of physical function, which is covered on our training pages.
Reading the research record
Myostatin is the cleanest example on this site of a spectacular animal result that did not transfer, and of why species labels matter. The 1997 mouse knockout is genuinely astonishing and it is a mouse. Two decades of human trials of myostatin-specific antibodies produced a string of null functional endpoints, the most quotable being a p value of 0.94.
The 2017 monkey study is the explanation, and it should be read before any claim about myostatin inhibition in humans: in primates the dominant restraint on muscle mass appears to be activin A. That single finding reorganises the field, predicts why broad receptor blockade outperformed ligand-specific blockade, and is almost never mentioned in consumer material about myostatin.
On supplements sold as myostatin inhibitors, the relevant context is that pharmaceutical-grade antibodies designed for exactly this target, dosed intravenously, mostly failed to change what patients could do. That is the bar.
The evidence, charted
Fig. 1 · evidence composition
4of 6 citations (67%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 6 distinct years, 1997 to 2025, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal1997
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member
Mouse. Myostatin-null mice are two to three times more muscular. The origin of the entire field, and a mouse result.
Nature - Animal2017
Activin A more prominently regulates muscle mass in primates than does GDF8
Cynomolgus monkey. In primates activin A, not myostatin, appears to be the dominant ligand restraining muscle mass. This is the single most important paper for understanding why pure anti-myostatin drugs underperformed in people.
Nature Communications - Human2004
Myostatin mutation associated with gross muscle hypertrophy in a child
One child, one loss-of-function mutation, extreme muscularity. It is a case report. It is not evidence that blocking myostatin is safe or useful at scale, and it is routinely cited as though it were.
New England Journal of Medicine - Human2020
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy
A pure anti-myostatin antibody against placebo. The difference in four-stair climb time at week 49 was 0.27 seconds, 95% CI minus 7.4 to 7.9, p = 0.94. No secondary clinical endpoint separated and muscle volume gains were not significant.
Neuromuscular Disorders - Human2025
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, placebo-controlled trial
The clear win in this pathway, and note what it blocks: apitegromab targets the activation of pro and latent myostatin rather than the mature protein. 188 participants across 48 hospitals in nine countries, all already on nusinersen or risdiplam.
Lancet Neurology - Human2021
Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial
Receptor-level blockade rather than myostatin-only blockade, so it neutralises activin A too. At 48 weeks fat mass fell 20.5% (7.5 kg) against 0.5% on placebo, lean mass rose 3.6% (1.7 kg), waist fell 9.0 cm and HbA1c fell 0.76 points, all p < 0.006.
JAMA Network Open
Frequently asked questions
Do myostatin inhibitor supplements work?
There is no human trial evidence that any oral supplement meaningfully inhibits myostatin or builds muscle through that mechanism. Worth holding in mind: purpose-built monoclonal antibodies against this exact target, given intravenously in randomised trials, mostly failed to improve function.
Why did the mouse result not translate?
The best available explanation is a monkey study showing that in primates activin A, not myostatin, is the dominant brake on muscle mass. Block myostatin alone in a primate and activin A is still doing most of the restraining.
Has anything in this pathway worked in humans?
Yes, two things, and neither is myostatin-only blockade. Apitegromab, which blocks myostatin activation rather than the mature protein, has positive phase 3 data in spinal muscular atrophy. Bimagrumab, which blocks the shared receptor, produced large changes in fat and lean mass in type 2 diabetes.
What about the muscular child?
That is one case report from 2004 describing a single child with a loss-of-function mutation. It establishes that the pathway matters in humans. It says nothing about whether blocking it in an adult is safe or useful, and it is cited as though it does.